Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
WHIST logo

A Randomised Controlled Trial of standard wound management versus negative pressure wound therapy in the treatment of adult patients having surgical incisions for major trauma to the lower limb

WHIST has now opened for recruitment in its first four pilot sites at Coventry, Nottingham, South Tees and Oxford. Sites at Bristol and Northumbria will follow shortly afterwards. The Pilot phase will confirm the expected rate of recruitment in this large-scale multi-centre randomised control trial.

We are currently contacting potential Main Phase sites at Major Trauma Centres across the UK to begin a gradual role out in October 2016.

Participants who are aged 16 years and older, who have sustained a lower limb fracture due to major trauma which requires a surgical incision, may be eligible to enter the trial.

The primary outcome measure is the rate of ‘deep infection,’ as per Centres for Disease Control and Prevention criteria, at 30 days

The secondary outcome measures include:

  • Disability Rating Index and general Health-related Quality of Life at 3 & 6 months and 5 years
  • Quality of wound healing
  • Further interventions related to the injury
  • Cost-effectiveness of Negative Pressure Wound Therapy versus standard dressing for wounds associated with major trauma to the lower limbs

For more information please visit: https://www.ndorms.ox.ac.uk/clinical-trials/current-trials-and-studies/whist

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.